MiMedx Group Inc MDXG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
MIMEDX to Participate in Upcoming Investor Conferences
MIMEDX Announces Third Quarter 2026 Operating & Financial Results
MIMEDX Announces $25 Million Patent License Agreement
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
MiMedx Gets Favorable Court Ruling in FDA Treatment-Classification Dispute
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
MIMEDX to Participate in Upcoming Investor Conferences
MiMedx Eliminates COO Role Amid Cost-Savings Push
Trading Information
- Previous Close Price
- $3.24
- Day Range
- $3.16–3.29
- 52-Week Range
- $3.03–7.51
- Bid/Ask
- $3.00 / $3.30
- Shares Outstanding
- 145.93M
- Market Cap
- $468.42M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 17.44
- Price/Sales
- 1.56
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.19%
Company Profile
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 808
- Website
- https://www.mimedx.com
Valuation
Metric | MDXG |
|---|---|
Price/Earnings (Normalized) | 17.44 |
Price/Book Value | 2.22 |
Price/Sales | 1.56 |
Price/Cash Flow | — |
Price/Earnings
MDXG
Financial Strength
Metric | MDXG |
|---|---|
Quick Ratio | 3.67 |
Current Ratio | 4.35 |
Interest Coverage | — |
Quick Ratio
MDXG
Profitability
Metric | MDXG |
|---|---|
Return on Assets (Normalized) | 1.84% |
Return on Equity (Normalized) | 2.39% |
Return on Invested Capital (Normalized) | 1.09% |
Return on Assets
MDXG
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%lf&<h | LOCK|#ct#N | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|%nCJx< | LOCK|SlHC | $99B | |||
| Moderna Inc MRNA | LOCK|H%CM@l | LOCK|@G | $90B | |||
| argenx SE ADR ARGX | LOCK|Mtcj<b% | LOCK|%k@ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|K?LkSv# | LOCK|@$ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>!<@YpZW | LOCK|dQ<& | $31B | |||
| Incyte Corp INCY | LOCK|%zrcn? | LOCK|zK@ | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|KnqP%T< | LOCK|HGV$ | $22B | |||
| BioNTech SE ADR BNTX | LOCK|YMz%Vz | LOCK|<# | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|Tc%T^# | LOCK|#F@ | $16B |
United States